JPH0141606B2 - - Google Patents
Info
- Publication number
- JPH0141606B2 JPH0141606B2 JP55178174A JP17817480A JPH0141606B2 JP H0141606 B2 JPH0141606 B2 JP H0141606B2 JP 55178174 A JP55178174 A JP 55178174A JP 17817480 A JP17817480 A JP 17817480A JP H0141606 B2 JPH0141606 B2 JP H0141606B2
- Authority
- JP
- Japan
- Prior art keywords
- glycerin
- drug
- ethyl
- methylethyl
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 23
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 11
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 description 13
- 239000007903 gelatin capsule Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 229960001066 disopyramide Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 229960001863 disopyramide phosphate Drugs 0.000 description 2
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- PYAPITOPBTXXNJ-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetamide Chemical compound C=1C=CC=NC=1C(C(=O)N)C1=CC=CC=C1 PYAPITOPBTXXNJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- -1 methylethyl Chemical group 0.000 description 1
- 208000008510 paroxysmal tachycardia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7931443A FR2471784A1 (fr) | 1979-12-21 | 1979-12-21 | Medicaments antiarythmiques a action prolongee dont le principe actif est le a/2-/bis (1-methylethyl) amino/ethyl/-a-phenyl-2-pyridine acetamide ou ses sels, ainsi que le procede de preparation de ces nouveaux medicaments et compositions les renfermant |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56118016A JPS56118016A (en) | 1981-09-16 |
JPH0141606B2 true JPH0141606B2 (ko) | 1989-09-06 |
Family
ID=9233075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP17817480A Granted JPS56118016A (en) | 1979-12-21 | 1980-12-18 | Long term functional antiarrhythmic drug whose active component is alphaa*22*bis*11 methylethyl*amino*ethyl**alphaaphenyll22 pyridineacetamide or one of salts* its manufacture and composition containi |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS56118016A (ko) |
AU (1) | AU543380B2 (ko) |
BE (1) | BE886774A (ko) |
CA (1) | CA1151067A (ko) |
DE (1) | DE3048154A1 (ko) |
FR (1) | FR2471784A1 (ko) |
GB (1) | GB2068226B (ko) |
IT (1) | IT1144024B (ko) |
MA (1) | MA19021A1 (ko) |
NL (1) | NL191171C (ko) |
PT (1) | PT72256B (ko) |
SE (1) | SE8007640L (ko) |
ZA (1) | ZA807807B (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982004392A1 (en) * | 1981-06-18 | 1982-12-23 | Uclaf Roussel | Method of preparing pharmaceutical compositions containing alpha-/2-/bis(1-methylethyl)amino/ethyl/alpha-phenyl 2-pyridine acetamide or one of its salts |
US4789549A (en) * | 1987-03-09 | 1988-12-06 | Warner-Lambert Company | Sustained release dosage forms |
JPH08143450A (ja) * | 1994-11-14 | 1996-06-04 | Taiyo Yakuhin Kogyo Kk | 徐放化製剤 |
JP5443768B2 (ja) * | 2006-03-16 | 2014-03-19 | ユーロセルティック ソシエテ アノニム | 医薬品球状物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3062720A (en) * | 1959-05-20 | 1962-11-06 | Philips Roxane | Sustained release pharmaceutical tablet |
FR2485M (fr) * | 1961-05-17 | 1964-04-27 | Searle & Co | Nouveaux régulateurs cardiaques. |
GB1021924A (en) * | 1962-06-22 | 1966-03-09 | Smith Kline French Lab | Improvements in or relating to method of preparing sustained release tablets |
BE708434A (ko) * | 1966-12-22 | 1968-05-02 |
-
1979
- 1979-12-21 FR FR7931443A patent/FR2471784A1/fr active Granted
-
1980
- 1980-10-30 SE SE8007640A patent/SE8007640L/ not_active Application Discontinuation
- 1980-12-12 ZA ZA00807807A patent/ZA807807B/xx unknown
- 1980-12-18 MA MA19224A patent/MA19021A1/fr unknown
- 1980-12-18 JP JP17817480A patent/JPS56118016A/ja active Granted
- 1980-12-19 DE DE19803048154 patent/DE3048154A1/de active Granted
- 1980-12-19 PT PT72256A patent/PT72256B/pt unknown
- 1980-12-19 IT IT50423/80A patent/IT1144024B/it active Protection Beyond IP Right Term
- 1980-12-19 NL NL8006938A patent/NL191171C/xx not_active IP Right Cessation
- 1980-12-19 BE BE0/203250A patent/BE886774A/fr not_active IP Right Cessation
- 1980-12-19 CA CA000367273A patent/CA1151067A/fr not_active Expired
- 1980-12-19 GB GB8040813A patent/GB2068226B/en not_active Expired
- 1980-12-19 AU AU65604/80A patent/AU543380B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
FR2471784A1 (fr) | 1981-06-26 |
IT8050423A0 (it) | 1980-12-19 |
NL191171B (nl) | 1994-10-03 |
CA1151067A (fr) | 1983-08-02 |
MA19021A1 (fr) | 1981-07-01 |
AU543380B2 (en) | 1985-04-18 |
NL8006938A (nl) | 1981-07-16 |
FR2471784B1 (ko) | 1982-12-17 |
IT1144024B (it) | 1986-10-29 |
DE3048154A1 (de) | 1981-09-03 |
BE886774A (fr) | 1981-06-19 |
PT72256A (fr) | 1981-01-01 |
JPS56118016A (en) | 1981-09-16 |
ZA807807B (en) | 1982-01-27 |
AU6560480A (en) | 1981-06-25 |
DE3048154C2 (ko) | 1992-03-19 |
GB2068226B (en) | 1984-03-21 |
PT72256B (fr) | 1982-07-15 |
GB2068226A (en) | 1981-08-12 |
NL191171C (nl) | 1995-03-01 |
SE8007640L (sv) | 1981-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2166394C (en) | Improved nicotine lozenge and therapeutic method for smoking cessation | |
US4956386A (en) | Pharmaceutical compositions and process for their preparation | |
JP4021507B2 (ja) | プロリン含有医薬組成物 | |
US5397574A (en) | Controlled release potassium dosage form | |
JPS6041610A (ja) | バルプロ酸をベ−スとした新規薬剤組成物及びその製法 | |
US4049803A (en) | Augmentation of blood levels of aspirin | |
AU2001249591A1 (en) | Sustained release beadlets containing stavudine | |
JPH069382A (ja) | 安定化された固型製剤およびその製造方法 | |
PT1334725E (pt) | Utilização de uma composição estroprogestativa como contraceptivo oral. | |
JPH0141606B2 (ko) | ||
CA1182049A (en) | Apap antacid composition | |
US6509035B1 (en) | Oral preparation of coenzyme a useful for lowering blood lipid and a method producing for same | |
JPH0140009B2 (ko) | ||
RU2240784C1 (ru) | Лекарственное средство на основе арбидола | |
GB2061111A (en) | Long acting pharmaceutical composition | |
JPS60163823A (ja) | 経口投与製剤 | |
RU2783944C1 (ru) | Фармацевтическая композиция, обладающая антиаритмической активностью различной этиологии | |
US3969525A (en) | Method for reducing the heart beat frequency | |
GB2175804A (en) | Treating cramp | |
RU2036642C1 (ru) | Способ получения бронхолитической лекарственной композиции пролонгированного действия на основе теофиллина | |
RU2276982C2 (ru) | Средство, обладающее противовоспалительным, анальгетическим, жаропонижающим действием в форме таблетки | |
US3642993A (en) | Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension | |
JPH0426676A (ja) | 新規ジテルペンアルカロイド及びジテルペンアルカロイド類を有効成分とする心疾患治療薬 | |
RU2191577C1 (ru) | Фармацевтическая противовоспалительная композиция и способ ее получения | |
RU2225713C1 (ru) | Фармацевтическая композиция, обладающая антиангинальным, антиишемическим и ноотропным действием |